MetaCap

Advanced Biomed (ADVB) vs Sera Prognostics (SERA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Sera Prognostics (SERA) has outperformed Advanced Biomed (ADVB) over the past year, losing 44.0% versus a loss of 77.8%. Sera Prognostics is the larger company by market cap ($72.0 million vs $2.7 million), about 26.4 times the size. Advanced Biomed converts more of its revenue into profit, with a net margin of 5231.3% versus -39417.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADVB-77.76%SERA-43.96%
+167%+39%-89%
Nov 21, 20251 yearNov 20, 2026
ADVB-97.74%SERA-58.10%
+15%-44%-103%
Mar 3, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADVB versus SERA key metrics
MetricADVBSERA
Share price$1.65$1.81
Market cap$2.73M$71.98M
1-day change-5.71%-4.23%
YTD return-71.75%-38.64%
1-year return-77.76%-43.96%
5-year return—-83.55%
EPS (TTM)$-5.03$-0.67
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$127.64K$81.00K
Revenue growth (YoY)—+5.19%
Net income (latest FY)$6.68M$-31.93M
Gross margin—-102.47%
Operating margin-4883.80%-45066.67%
Net margin5231.30%-39417.28%
52-week high$24.23$3.85
52-week low$1.58$1.56
Distance from 52-week high-93.19%-52.99%
Analyst consensus—none
Avg. price target upside—+203.87%
Average volume88.38K27.84K
Shares outstanding1.65M38.80M
Employees3171
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Sera Prognostics is about 26.4 times larger than Advanced Biomed by market value ($71.98M vs $2.73M).
  • SERA has outperformed ADVB by 33.8 percentage points over the past year.
  • Advanced Biomed is more profitable, keeping 5231.3 cents of every revenue dollar as net income versus -39417.3 cents for Sera Prognostics.

About Advanced Biomed

ADVB stock →

Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product.

Health Care · Medical Specialities · 31 employees

About Sera Prognostics

SERA stock →

Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.

Health Care · Medical Specialities · 71 employees

ADVB vs SERA FAQ

Which is bigger, Advanced Biomed or Sera Prognostics?

Sera Prognostics (SERA) is larger, with a market capitalization of $71.98M compared with $2.73M for Advanced Biomed (ADVB).

Which stock has performed better over the past year, ADVB or SERA?

SERA returned -43.96% over the past 12 months, compared with -77.76% for ADVB (price return, excluding dividends). Past performance does not predict future results.

Are Advanced Biomed and Sera Prognostics in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons